Agoracom Blog Home

Archive for the ‘Empower Clinics Inc.’ Category

VIDEO – Empower Clinics $CBDT.ca Grows Revenue 416% To $USD 790,000 In Q1 – BEFORE COVID-19 Revenues Commenced In Q2 $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca

Posted by AGORACOM-JC at 5:36 PM on Wednesday, July 29th, 2020

Sometimes, you just have to let the numbers speak for themselves.  With 165,000 patients, Empower Clinics (CBDT:CSE) (EPWCF:OTCQB) has a database that almost every medical cannabis and CBD company would kill for …

but then these numbers came in for:   2019 – Year Ended DEC 31, 2019 Q4 – Quarter Ended DEC 31, 2019 Q1 – Quarter Ended MAR 31, 2020  

Patient Visits

  • 2019 +110% To 15,900
  • Q4 + 251% To 4,616
  • Q1 + 377% To 5,717 (PRE COVID REVENUES COMMENCING Q2)

Revenues $USD

  • 2019 + 86% To $2.03M
  • Q4 + 217% To $625,000
  • Q1 + 416% To $790,000  (PRE COVID REVENUES COMMENCING Q2)  

Do you see a trend?   

We can’t wait for Q2 numbers (April, May, June) because we already know patient visits for April alone were up over 870%.   

Looking even further forward into Q3 (July, August, September), we already know that July patient visits are going to set a record.    

Though CBDT had a very short cease trade order due to the delay in getting these financials filed…. the wait was clearly worth it, as was this interview with CEO, Steven McAuley,  who is Six Sigma certified under the quality initiative of legendary GE (General Electric) Chairman Jack Welch. We’ve never seen a Six Sigma certified CEO in the Canadian small cap markets. Never …. which explains how McAuley has been able to guide Empower Clinics through the most disruptive retail environment in recent history and turn it into significant growth.  

Watch this interview or listen by Podcast on AppleGoogleSpotify or your favourite podcaster.

Empower Clinics $CBDT.ca Reports Q1 2020 Results with 416% Revenue Increase $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca

Posted by AGORACOM-JC at 7:14 AM on Tuesday, July 28th, 2020
  • 5,717 patient visits generating total revenue of $789,135, compared to 1,198 patient visits generating $152,846 for Q1 2019

VANCOUVER, BC / July 28, 2020 / EMPOWER CLINICS INC. (CSE:CBDT) (OTCQB:EPWCF) (Frankfurt:8EC)(“Empower” or the “Company“) has filed today its unaudited interim condensed consolidated financial statements and related management’s discussion and analysis, both of which are available at www.SEDAR.com. All financial information in this press release is reported in United States dollars, unless otherwise indicated.

“Our strong Q1 2020 performance is a direct reflection of the numerous changes and improvements from 2019, setting in motion a framework for sustained growth.” said Steven McAuley, Chairman and CEO. “Our Sun Valley Health division started the year with record patient visits and now offers more diversified wellness services, adding new revenue sources and a more diversified business model.”

Q1 2020 Highlights

  • 5,717 patient visits generating total revenue of $789,135, compared to 1,198 patient visits generating $152,846 for Q1 2019.
  • Net loss of $524,208 or $0.00 per share, compared to $398,541 or $0.01 per share for Q1 2019, which was primarily driven by increased non-cash accretion expense.
  • Cash provided by operating activities was $13,864, compared to cash used by operating activities of $219,212 for Q1 2019.
  • Cash at March 31, 2020 of $131,808, compared to cash of $179,152 at December 31, 2019.

Recent Highlights Subsequent to Quarter End

  • Private Placement: Empower Clinics closes private placement of $653,000 CAD in April 2020 and $720,866 CAD in July 2020 to support growth initiatives.
  • Psychedelics Division: May 2020 Empower enters into a term sheet to acquire an interest in the global royalty rights of Dosed Movie, launches Dosed Wellness, a psychedelics brand, launches new dedicated website www.dosedwellness.com and adds new team members dedicated to the new brand.
  • COVID-19 Testing: April 2020 the Company launches a four-phase roll-out of COVID-19 testing in clinics and onsite for businesses.
  • Cannvas Education Platform: May 2020 Empower and EuroLife Brands complete definitive agreement for multi-year, multi-national licence of EurolIfe’s cannvas.me web-based education technology platform to deliver brand, product, and industry knowledge to the market.

Financial Summary

$, except where notedThree months ended March 31,
 20202019 
Patient visits (#)5,7171,198 
Clinic Revenues767,803152,846 
Direct Clinic Expenses256,42239,413 
Loss from operations(317,831)(279,308) 
Net loss(524,208)(398,541) 
Net loss per share(0.00)(0.01) 

Financial Performance

Clinic revenues for Q1 2020 and Q1 2019 were $767,803 and $152,846, respectively. This increase above prior year is attributable to the acquisition of Sun Valley and the addition of 5 clinics which drove an increase in patient count from 1,198 in Q1 2019 to 5,717 in Q1 2020.

Direct clinic expenses for Q1 2020 and Q1 2019 were $256,422 and $39,413, respectively. This increase above prior year is attributable to the increase in number of patient visits.

Net loss from operations for Q1 2020 and Q1 2019 were $317,831 and $279,308, respectively. This increase above prior year is primarily attributable to an increase in salaries and benefits with the acquisition of Sun Valley. This decrease was partially offset by an increase in clinic revenues with the acquisition of Sun Valley.

Net loss for Q1 2020 and Q1 2019 were $524,208 and $398,541, respectively. This increase over prior year is primarily attributable to non-cash accretion expense related to the convertible debentures.

During the three months ended March 31, 2020, the Company generated $13,864 in cash from operations after changes in non-cash working capital. The Company used $61,209 for payment of lease liabilities.

Please refer to the Company’s unaudited condensed interim consolidated financial statements for the three months ended March 31, 2020 and 2019, and accompanying Management Discussion and Analysis for a full review of the operations.

About Empower

Empower is a vertically integrated health & wellness company with a network of corporate and franchised health & wellness clinics in the U.S. The Company is focused on helping patients improve and protect their health, through innovative physician recommended treatment options. The Company has launched Dosed Wellness Ltd. to connect its significant data, to the potential of the efficacy of alternative treatment options related to hemp-derived cannabidiol (CBD) therapies, psilocybin and other psychedelic plant-based treatment options.

ON BEHALF OF THE BOARD OF DIRECTORS:
Steven McAuley
Chief Executive Officer

CONTACTS:

InvestorsDustin Klein Steven McAuley
 Director CEO
 720-352-1398 604-789-2146
 [email protected] [email protected]

DISCLAIMER FOR FORWARD-LOOKING STATEMENTS

This news release contains certain “forward-looking statements” or “forward-looking information” (collectively “forward looking statements”) within the meaning of applicable Canadian securities laws. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Forward-looking statements can frequently be identified by words such as “plans”, “continues”, “expects”, “projects”, “intends”, “believes”, “anticipates”, “estimates”, “may”, “will”, “potential”, “proposed” and other similar words, or information that certain events or conditions “may” or “will” occur. Forward-looking statements in this news release include, but are not limited to, statements regarding the direction and growth prospects of the Company, the expansion of the company’s clinic and distribution network, the expected effect of the Vendors in their new roles with the Company, the effect on the lives of patients, the growth into a national brand, the effect of the Transaction, the diversification of the Company’s business model, the potential appeal to shareholders, the growth of the Company’s patient list and the effect thereof, the expected benefits for the company’s patient base and customers, the release of the cash consideration, the release of Shares being held in escrow in connection with the Transaction and statements regarding the Company’s proprietary product line “Sollievo”. Such statements are only projections, are based on assumptions known to management at this time, and are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including that the Company may not be able to expand, that the Transaction may not have the expected results, and other factors beyond the Company’s control. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are cautioned not to place undue reliance on the forward-looking statements in this release, which are qualified in their entirety by these cautionary statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements in this release, whether as a result of new information, future events or otherwise, except as expressly required by applicable laws.

SOURCE: Empower Clinics Inc.

Empower Clinics $CBDT.ca Reports Fiscal 2019 Results $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca

Posted by AGORACOM-JC at 7:19 AM on Friday, July 24th, 2020

– 15,920 patient visits generating total revenue of $2,031,581 or $0.02 per share, compared to 7,607 patient visits generating $1,091,386 or $0.02 per share for fiscal 2018.

VANCOUVER, BC /July 24, 2020 / EMPOWER CLINICS INC. (CSE:CBDT)(OTC PINK:EPWCF)(Frankfurt:8EC)(“Empower” or the “Company“) has filed today its audited consolidated financial statements and related management’s discussion and analysis, both of which are available at www.SEDAR.com. All financial information in this press release is reported in United States dollars, unless otherwise indicated.

“2019 is defined by profound change for our Company setting the stage for the ongoing transition to a growth-oriented health & wellness brand, with substantially improved operating controls and improved cost structure.” said Steven McAuley, Chairman and CEO. “As we look ahead navigating a global pandemic, we find ourselves thriving, hiring and seeing patients in record numbers, further supporting our diversification to broader wellness services.”

2019 Highlights

  • 15,920 patient visits generating total revenue of $2,031,581 or $0.02 per share, compared to 7,607 patient visits generating $1,091,386 or $0.02 per share for fiscal 2018.
  • Net loss of $4,301,663 or $0.04 per share, compared to $3,789,918 or $0.06 per share for fiscal 2018, which was primarily driven by the recognition of goodwill and intangible asset impairment losses related to the Sun Valley acquisition which arose due to changes in Arizona licensing requirements.
  • Cash used in operating activities was $2,273,188 or $0.02 per share, compared to $2,835,711 or $0.04 per share for fiscal 2018.
  • Cash at December 31, 2019 of $179,153, compared to cash of $157,668 at December 31, 2018.

Recent Highlights Subsequent to Year End

  • Private Placement: April 2020 Empower Clinics closes private placement of $653,000 CAD to support growth initiatives.
  • Psychedelics Division: May 2020 Empower enters into a term sheet to acquire an interest in the global royalty rights of Dosed Movie, launches Dosed Wellness, a psychedelics brand, launches new dedicated website www.dosedwellness.com and adds new team members dedicated to the new brand.
  • COVID-19 Testing: April 2020 the Company launches a four-phase roll-out of COVID-19 testing in clinics and onsite for businesses.
  • Cannvas Education Platform: May 2020 Empower and EuroLife Brands complete definitive agreement for multi-year, multi-national licence of EurolIfe’s cannvas.me web-based education technology platform to deliver brand, product, and industry knowledge to the market.
  • Private Placement: July 2020 Empower Clinics closes private placement of $720,866 to support growth initiatives.

Financial Summary

Financial Performance

Clinic revenues for Q4 and full year 2019 were $542,677 and $1,949,549, respectively, compared to Q4 and full year 2018 revenues of $196,909 and $1,091,386, respectively. This increase above prior year is attributable to the acquisition of Sun Valley and the addition of 5 clinics which drove an increase in patient count from 7,607 in fiscal 2018 to 15,920 in fiscal 2019.

Direct clinic expenses for Q4 and full year 2019 were $615,814 and $826,276, respectively, compared to Q4 and full year 2018 direct clinic expenses of $115,655 and $417,047, respectively. This increase above prior year is attributable to the increase in number of patient visits.

Net loss from operations for Q4 and full year 2019 were $1,132,784 and $3,680,060, respectively, compared to Q4 and full year 2018 net loss of $592,899 and $4,309,373, respectively. This decrease below prior year is primarily attributable to the increase in net clinic revenues. While there was an increase in salaries and wages with the acquisition of Sun Valley, this increase was offset by a decline in share-based payments and legal and professional fees.

Net loss for Q4 and net loss for the full year 2019 were $1,942,084 and $4,301,663, respectively, compared to Q4 and full year 2018 net income of $1,342,930 and net loss of $3,789,918, respectively. This increase over prior year is primarily attributable to the recognition of goodwill and intangible asset impairment of $2,377,397 and $93,757, respectively. Partially offsetting these one-time expenses is an increase in the gain recognized on the warrant liability and conversion feature associated with the convertible debentures that resulted from the decrease in the Company’s share price and therefore the value of the warrants and convertible debentures exercisable.

During the year ended December 31, 2019, the Company used $2,273,188 in cash from operations after changes in non-cash working capital. The Company invested $3,828 towards property and equipment and raised $3,085,819 via proceeds from various issuances of shares, notes, and convertible debentures.

Please refer to the Company’s audited consolidated financial statements, related notes and accompanying Management Discussion and Analysis for a full review of the operations.

About Empower

Empower is a vertically integrated health & wellness company with a network of corporate and franchised health & wellness clinics in the U.S. The Company is focused on helping patients improve and protect their health, through innovative physician recommended treatment options. The Company has launched Dosed Wellness Ltd. to connect its significant data, to the potential of the efficacy of alternative treatment options related to hemp-derived cannabidiol (CBD) therapies, psilocybin and other psychedelic plant-based treatment options.

ON BEHALF OF THE BOARD OF DIRECTORS:
Steven McAuley
Chief Executive Officer

CONTACTS:

InvestorsDustin Klein Steven McAuley
 Director CEO
 647-620-5101 604-789-2146
 [email protected] [email protected]

DISCLAIMER FOR FORWARD-LOOKING STATEMENTS

This news release contains certain “forward-looking statements” or “forward-looking information” (collectively “forward looking statements”) within the meaning of applicable Canadian securities laws. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Forward-looking statements can frequently be identified by words such as “plans”, “continues”, “expects”, “projects”, “intends”, “believes”, “anticipates”, “estimates”, “may”, “will”, “potential”, “proposed” and other similar words, or information that certain events or conditions “may” or “will” occur. Forward-looking statements in this news release include, but are not limited to, statements regarding the direction and growth prospects of the Company, the expansion of the company’s clinic and distribution network, the expected effect of the Vendors in their new roles with the Company, the effect on the lives of patients, the growth into a national brand, the effect of the Transaction, the diversification of the Company’s business model, the potential appeal to shareholders, the growth of the Company’s patient list and the effect thereof, the expected benefits for the company’s patient base and customers, the release of the cash consideration, the release of Shares being held in escrow in connection with the Transaction and statements regarding the Company’s proprietary product line “Sollievo”. Such statements are only projections, are based on assumptions known to management at this time, and are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including that the Company may not be able to expand, that the Transaction may not have the expected results, and other factors beyond the Company’s control. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are cautioned not to place undue reliance on the forward-looking statements in this release, which are qualified in their entirety by these cautionary statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements in this release, whether as a result of new information, future events or otherwise, except as expressly required by applicable laws.

Empower Clinics $CBDT.ca Announces Closing of Private Placement Increased Demand for COVID-19 Testing and Are on Pace for Record July Patient Visits $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca

Posted by AGORACOM-JC at 1:29 PM on Thursday, July 16th, 2020
  • Closes private placement of $720,866.00 to support the Company growth plan
  • Continues to meet increased demand for COVID-19 testing in Arizona clinics, along with supporting record patient demand in July 2020

VANCOUVER, BC / July 16, 2020 / EMPOWER CLINICS INC. (CSE:CBDT)(Frankfurt:8EC)(OTCQB:EPWCF) (“Empower” or the “Company“), a life sciences company, is pleased to announce the closing of its non-brokered private placement of an aggregate of 14,417,334 units of the Company (each, a “Unit“) at a price of $0.05 per Unit for gross proceeds of $720,866.00 (the “Offering“).

The proceeds of the Offering are expected to be used by the Company for general working capital and corporate purposes and to support the launch if it’s previously announced psychedelics division Dosed Wellness Ltd. www.dosedwellness.com

The Company also continues to see strong demand for COVID-19 testing supported by an expansion to five-day per week testing schedule in Phoenix, AZ clinics. In addition, Sun Valley Health has added ten (10) new hires and (4) internal management promotions in the past 30 days to manage the increased volumes of patients, that are anticipated to reach record levels in July 2020.

“Our clinic team continue to provide exemplary support and care for patients, in a safe and compassionate manner,” said Steven McAuley, Chairman & CEO. “Successfully accessing the capital markets to support growth allows the Company to advance its ongoing plan of providing diversified health & wellness services and positioning us to become a long-term market leader.”

Each Unit is comprised of one Share and one Warrant, with each Warrant exercisable into one Warrant Share at an exercise price of $0.12 per Warrant Share for a period of two years following the Closing.

The Units, and the underlying Shares, Warrants and Warrant Shares (collectively, the “Securities“), are subject to restrictions on resale under applicable Canadian securities laws for a period of four months and one day from the closing of the Offerings. None of the Securities have been or will be registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements. This news release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities, in any jurisdiction in which such offer, solicitation or sale would require registration or otherwise be unlawful.

ABOUT EMPOWER

Empower is a vertically integrated health & wellness company with a network of corporate and franchised health & wellness clinics in the U.S. The Company is focused on helping patients improve and protect their health, through innovative physician recommended treatment options. The Company has launched Dosed Wellness Ltd. to connect its significant data, to the potential of the efficacy of alternative treatment options related to hemp-derived cannabidiol (CBD) therapies, psilocybin and other psychedelic plant-based treatment options.

ON BEHALF OF THE BOARD OF DIRECTORS:

Steven McAuley
Chief Executive Officer

Investors: Dustin Klein
Director
[email protected],com
720-352-1398

Investors: Steven McAuley
CEO
[email protected]
604-789-2146

For French inquiries: Remy Scalabrini, Maricom Inc., E: [email protected], T: (888) 585-MARI

DISCLAIMER FOR FORWARD-LOOKING STATEMENTS

This news release contains certain “forward-looking statements” or “forward-looking information” (collectively “forward looking statements”) within the meaning of applicable Canadian securities laws. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Forward-looking statements can frequently be identified by words such as “plans”, “continues”, “expects”, “projects”, “intends”, “believes”, “anticipates”, “estimates”, “may”, “will”, “potential”, “proposed” and other similar words, or information that certain events or conditions “may” or “will” occur. Forward-looking statements in this news release include statements regarding; the Company’s intention to open a hemp-based CBD extraction facility, the expected benefits to the Company and its shareholders as a result of the proposed acquisitions and partnerships; the effectiveness of the extraction technology; the expected benefits for Empower’s patient base and customers; the benefits of CBD based products; the effect of the approval of the Farm Bill; the growth of the Company’s patient list and that the Company will be positioned to be a market-leading service provider for complex patient requirements in 2019 and beyond. Such statements are only projections, are based on assumptions known to management at this time, and are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including; that the Company may not open a hemp-based CBD extraction facility; that legislative changes may have an adverse effect on the Company’s business and product development; that the Company may not be able to obtain adequate financing to pursue its business plan; general business, economic, competitive, political and social uncertainties; failure to obtain any necessary approvals in connection with the proposed acquisitions and partnerships; and other factors beyond the Company’s control. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are cautioned not to place undue reliance on the forward-looking statements in this release, which are qualified in their entirety by these cautionary statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements in this release, whether as a result of new information, future events or otherwise, except as expressly required by applicable laws.

Empower Clinics $CBDT.ca – #Psychedelic Therapists Petition Government For Permission To Dose Themselves In Order To Better Treat Patients $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca

Posted by AGORACOM-JC at 5:40 PM on Wednesday, July 15th, 2020

SPONSOR:

  • A leading owner/operator of physician staffed health and pain management clinics.
  • Patient database of over 165,000 patients 
  • Proprietary technology platforms including Electronic Health Records portal and e-Commerce for CBD product distribution
  • Recently launched CBD extraction facility
  • First extraction system capacity = 2,300 Kg per year.
  • CBD based products are poised to be a $20B global industry by 2022
  • Medical cannabis is poised to be a $100B global industry by 2025
  • Company to create Psilocybin and Psychadelics Division leveraging corporate wellness clinics and franchise clinic
  • Commenced tele-medicine services for patients, both in-clinics and virtually through secure video, on browser and in mobile app
  • Successfully conducted COVID-19 antibody business employee testing, solidifying the importance of phase three of the testing program
  • Conducted 2,302 physician-patient consultations setting a new milestone in patient volume for the month of May

———

Psychedelic Therapists Petition Government For Permission To Dose Themselves In Order To Better Treat Patients

  • “The fundamental reason to expose therapists to their own experiences with psychedelics is that, unless you have visited these realms, you are unlikely to understand their importance.”

By Ben Adlin

As a group of terminally ill patients in Canada awaits word from the minister of health on whether they can legally access psychedelic mushrooms for end-of-life care, their team of clinicians has tacked on an additional request: The therapists want to be able to dose themselves, too.

The group behind the request, Victoria, B.C.–based TheraPsil, a nonprofit that aims to expand access to psilocybin-based psychotherapy in Canada, says the additional step of providing safe access for therapists will ensure they gain firsthand experience into the psilocybin’s effects and its applications to psychotherapy.

“The fundamental reason to expose therapists to their own experiences with psychedelics is that, unless you have visited these realms, you are unlikely to understand their importance.”

“Part of ensuring a very high-quality psychedelic treatment for patients is to ensure high-quality training for therapists,” Spencer Hawkswell, TheraPsil’s executive director, told Marijuana Moment in an interview. “It’s greatly beneficial if therapists have had psychedelic therapy themselves.”

Few people, he offered by analogy, “would advise going to a sex therapist who’s never had sex before.”

TheraPsil, founded by clinical psychologist and psychotherapist Bruce Tobin, has been fighting for expanded access to psilocybin end-of-life care for years. In 2017, the group first filed a petition to exempt patients with certain terminal conditions from Canada’s ban on psilocybin. It was reportedly the first time a therapist had asked the Canadian government for such an exemption.

It wasn’t until this past January that TheraPsil finally heard back, Hawkswell said. “After three years of back-and-forth, they got back to us and said, ‘We’re going to be rejecting this application.’” The agency said there was no obvious medical necessity for the psychedelics.

TheraPsil was undaunted. “They say there’s no necessity,” Hawkswell said. “Maybe it’s because they haven’t met that person yet.”

In April, the group helped four more people with terminal illnesses file petitions with Health Canada and Health Minister Patty Hajdu seeking exemptions that will allow them to access psilocybin. In an interview with Marijuana Moment, Hawkswell said patients had gone months so far without a word from Hajdu, who with a stroke of a pen could allow the patients to access the drug.

“What we are working on right now is ramping up our messaging,” Hawkswell said. “We are going to try everything we can to get to the minister to make sure she sees these patients and responds to them.”

Dear @PattyHajdu, today marks the 75th day that palliative Canadians have been waiting on a reply from YOU re: their section 56 exemptions for compassionate access to #psilocybin. In the words of Dr. Bruce Tobin, TheraPsil’s founder: “Please, do not make them wait any longer” pic.twitter.com/JRITGwtcMR

— TheraPsil (@TheraPsil) July 6, 2020

Efforts to allow TheraPsil’s clinicians to use psilocybin themselves are more recent. Dr. Sean O’Sullivan, an emergency room physician and psychotherapist who serves on TheraPsil’s board of directors, said the exemptions are necessary so that therapists can be better trained and more familiar with how psychedelics work in a therapeutic setting.

“The fundamental reason to expose therapists to their own experiences with psychedelics is that, unless you have visited these realms, you are unlikely to understand their importance,” O’Sullivan told Marijuana Moment. “The point is to allow therapists to understand the field they’re plowing in.”

Therapists need to be alert and able to recognize how psychedelic experiences manifest themselves in therapy, O’Sullivan said. Patients might bring up material having to do with their own birth, a traumatic experience or interactions with otherworldly beings. “If you’re not attuned to this possibility, not aware of this possibility, then it’s just going to slide by you,” he said. 

“It’s a bit like describing Beethoven’s Fifth,” O’Sullivan added. “You can describe it all you like, but at some point you have to play the music.”

As psychedelic therapy is more widely sought by patients, O’Sullivan said, demand for qualified therapists is likely to go up. “We are expecting that as we get more permission for patients to access psilocybin at the end of life,” he said, “that there will be an increase in demand for therapists that have had that psychedelic experience.”

Public opinion in Canada generally supports allowing access to psilocybin therapy for the terminally ill, TheraPsil says. A poll released by the group last month found that 59 percent of Canadians support legal access. Including respondents who said they were “ambivalent,” TheraPsil said, acceptance increased to 78 percent.

“What’s unreasonable is the political decision” to deny patients access to psilocybin, Hawkswell argued. “It’s not a scientific one, it’s not a democratic one. It’s political.”

Patients facing their imminent death often experience feelings and fears that psychedelics can help to ease, he said. Among them are demoralization, anxiety and depression. Existing treatment includes pharmaceuticals, talk therapy and occasionally inpatient treatment.

Psychedelics play a role in treatment by inducing what Hawkswell and others refer to as a “mystical experience”—a collection of psychoactive and sometimes spiritual events that accompany a psychedelic journey. The experience can reorient a person’s way of thinking, dissolving barriers between an individual and the world around them. For end-of-life patients, he explained, it can help them embrace that death “is natural—just as natural as being born.”

Practitioners note that psychedelic therapy doesn’t work the same way as many other pharmaceutical drugs, such as antidepressants or even medical marijuana. Patients usually take those substances under their own supervision and allow them to work in the background. With therapeutic use of psilocybin and other psychedelics, patients typically take the drug and undergo guided psychotherapy. Psychedelics’ unusual, sometimes disorienting effects are believed to allow patients to better approach and engage obstacles, then emerge with a fresh perspective.

Another psychedelic therapy group, Field Trip, which uses ketamine in therapy, describes the treatment on their website as a way “to press reset on your mental health.”

The emerging promise of psychedelics in recent years have caught the attention of academics, public policy reformers and even the U.S. government. Last month, the University of North Carolina (UNC) announced a $27 million project funded by the department of defense to research and develop psychedelics-inspired drugs.

That project’s researchers seem to believe they can separate psychedelics from what they describe as “disorienting” side effects, despite what Hawkswell and others say about the importance of a “mystical experience.”

“Although drugs like ketamine and potentially psilocybin have rapid antidepressant actions, their hallucinogenic, addictive, and disorienting side effects make their clinical use limited,” said Bryan L. Roth, a professor of pharmacology at UNC School of Medicine and the research team’s leader. The government partnership, UNC said, “aims to create new medications to effectively and rapidly treat depression, anxiety, and substance abuse without major side effects.”

In September of last year, Johns Hopkins University announced the launch of the nation’s first-ever psychedelic research center, a $17-million project to study the use of psychedelics to treat conditions such as opioid use disorder, Alzheimer’s disease, depression, anxiety and post-traumatic stress disorder.

Meanwhile, activists in the United States have advocated for state- and local-level reforms to research, decriminalize and in some cases even legalize psychedelics themselves.

At the municipal level, Denver became the first U.S. city to enact such a reform, with voters in May 2019 approving a measure to effectively decriminalize possession of psilocybin mushrooms. Soon after, officials in Oakland, California, decriminalized possession of all plant- and fungi-based psychedelics. In January of this year, Oakland activists unveiled plans to allow go further and legalize the commercial sale of natural entheogenic substances. That same month in nearby Santa Cruz, the City Council effectively decriminalized psychedelics by voting to make the enforcement of laws against them among the city’s lowest enforcement priorities.

Reformers are now pushing for similar changes in other jurisdictions. In Washington, D.C. this month, Decriminalize Nature D.C. submitted signatures to qualify a measure for November’s ballot that would decriminalize all natural psychedelic drugs, including psilocybin, ayahuasca and ibogaine.

Other reform efforts are ongoing in Oregon, where voters later this year will decide whether to legalize psilocybin therapy—the very therapy TheraPsil’s patients are pushing Canadian Health Minister Hajdu to allow. Oregon voters will also see a separate measure to decriminalize the possession of all drugs and expand access to treatment for problem use on their November ballot.

Lawmakers in Hawaii earlier this year approved a plan to study psilocybin mushrooms’ medical applications with the goal of eventually legalizing access.

In Canada, for now, psilocybin remains illegal. Hawkswell of TheraPsil, however, believes a constellation of other national policies—including medical marijuana, safe injection sites, and physician-assisted dying—support extending psilocybin access to patients in palliative care. And Canada already permits certain religious groups to use ayahuasca as religious sacrament, Hawkswell noted.

“At this point psilocybin is a reasonable medical choice for these individuals,” he told Marijuana Moment. “This is about the minister being compassionate and using her ministerial abilities to help give patients access to something that’s going to help them.”

Patients waiting to hear back from Hajdu’s office, he said, don’t have time to wait for lengthy, bureaucratic processes. “We’re not just going to keep waiting,” he told Marijuana Moment. “We do have a legal team prepared, but that’s all I’ll say.”

Source: https://www.marijuanamoment.net/psychedelic-therapists-petition-government-for-permission-to-dose-themselves-in-order-to-better-treat-patients/

Empower Clinics $CBDT.ca – 5 positive testimonials on medical marijuana benefits from real patients $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca

Posted by AGORACOM-JC at 4:30 PM on Monday, July 6th, 2020

SPONSOR:

Why Empower Clinics

  • A leading owner/operator of physician staffed health and pain management clinics.
  • Patient database of over 165,000 patients 
  • Proprietary technology platforms including Electronic Health Records portal and e-Commerce for CBD product distribution
  • Recently launched CBD extraction facility
  • First extraction system capacity = 2,300 Kg per year.
  • CBD based products are poised to be a $20B global industry by 2022
  • Medical cannabis is poised to be a $100B global industry by 2025
  • Company to Create Psilocybin and Psychadelics Division Leveraging Corporate Wellness Clinics and Franchise Clinic
  • Commenced tele-medicine services for patients, both in-clinics and virtually through secure video, on browser and in mobile app
  • Successfully conducted COVID-19 antibody business employee testing, solidifying the importance of phase three of the testing program
  • Conducted 2,302 physician-patient consultations setting a new milestone in patient volume for the month of May

—————————

5 positive testimonials on medical marijuana benefits from real patients

By: Pearce Thompson

We’d like to shine a light on a few patients in this article, to share their insights and experiences on how medical marijuana has benefited them throughout their illness. Please take the time to read through the list of 5 testimonials from real patients who have had positive outcomes from using the herb for their treatments.

If you want to view the history of medical marijuana referenced above, click here. If you want a timeline of the history of medical marijuana use in Canada, click here.

#1 Rebecca Swell an advocate of medical marijuana

When Rebecca was 10 years old she was diagnosed with Complex Regional Pain Syndrome, this condition comes from damage to the nervous system and causes extreme pain. Rebecca was forced into a walker or wheelchair from a young age, and when spinal cord stimulation and morphine didn’t work, she tried medical marijuana. Rebecca now needs no walking support, no morphine, and is an advocate of medical marijuana.

#2 Charlotte Figgi (Charlotte’s Web)

The story of Charlotte Figgi is more well known than most. Charlotte was diagnosed with a rare form of epilepsy at a young age and at 5 she experienced close to 300 mal seizures per week. The condition was so bad the doctor put her in a medically induced coma. In the first week of trying cannabis oil, Charlotte had no seizures. The strain created for her has no psychoactive effects and was renamed “Charlotte’s Web“.

#3 Ashley Surin

Ashly was diagnosed with Acute Lymphoblastic Leukemia, a type of cancer that affects white blood cells which makes it harder to fight infections. Ashley was also prone to seizures and her family moved to cannabis oil to aid this. The oil proved effective and is still used by Ashley to this day.

#4 Walter Rodlund

Walter Rodlund is from Fargo, ND and at the age 81 he enjoyed spending time outdoors his entire life. At this time he was diagnosed with Chronic Obstructive Pulmonary Disease, which decreased his lung capacity. With this condition, Walter could no longer enjoy the outdoors. His daughter recommended cannabis oil, Walter tried, Walter liked, Walter enjoys the outdoors again.

5. Beyla Pagano benefitted a lot by taking medical marijuana

From birth, Beyla had a large amount of cerebrospinal fluid built up in her brain. This caused seizures and doctors believed she would never walk or talk. The prescriptions given to her always put her in a drowsy state, so her family tried medical marijuana. The cannabis oil immediately improved her state, Beyla can walk, talk, and has seizures less frequently.

Empower $CBDT.ca #Covid19 Testing to Expand to Five Days Per Week and June 2020 Patient Visits Set Records $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca

Posted by AGORACOM-JC at 8:23 AM on Friday, July 3rd, 2020
  • Empower is expanding its COVID-19 testing to five days per week to meet demand
  • June 2020 patient volume surpasses 2,100 patients visits, a company record for the month of June

VANCOUVER, BC / July 3rd, 2020 / EMPOWER CLINICS INC. (CSE:CBDT) (OTCQB:EPWCF) (Frankfurt:8EC) (“Empower” or the “Company“), a life sciences company, is pleased to announce the Company is expanding COVID-19 testing days to meet the increasing demand in the State of Arizona. In addition, the Company conducted 2,130 physician-patient consultations setting a new historic milestone in patient volume for the month of June.

“As a company and a health & wellness clinic operator, we are fortunate to be able to provide care and support to our thousands of patients each month.” said Steven McAuley, Chairman & CEO of Empower. “The demand for our services, are at an all-time high, requiring us to hire new staff and extend hours of operation. Our team continues to perform with complete professionalism, and safety, knowing the importance of the physician consultations we provide.”

The Arizona Department of Health Services has reported that in the last seven (7) days, nearly 25,000 positive cases of coronavirus have been reported, representing more than 25% of the total cases in the state of Arizona since the pandemic first started in late January 2020. Total reported cases now exceed 87,000 in the state.

As previously disclosed, the Company submitted an application for a management cease trade order (“MCTO“) with the British Columbia Securities Commission. The Company confirms that the BC Securities Commission has approved the application for the MCTO effective June 16, 2020

As required under section 9 b) of the National Policy 12-203 – Cease Trade Orders the Company indicates it is unable to meet the prescribed filing deadline due to additional audit requirements by its auditor MNP, LLP and due to increased operational limitations related to the coronavirus pandemic. The Company continues to expect to file the annual filings, no later than July 15, 2020.

The Company intends to comply with the provisions of the alternative information guidelines as set out in the National Policy 12-203 – Cease Trade Orders for Continuous Disclosure Defaults for as long as it remains in default, including the issuance of bi-weekly default status reports, each of which will be issued in the form of a news release.

As required under Canadian securities laws, the Company will provide a further update on or about July 14, 2020. Additionally, to the knowledge of the Company, there have been no material business developments as of the date of this news release that have not been generally disclosed.

ABOUT EMPOWER

Empower is a vertically integrated health & wellness company with a network of corporate and franchised health & wellness clinics in the U.S. The Company is focused on helping patients improve and protect their health, through innovative physician recommended treatment options. The Company has launched Dosed Wellness Ltd. to connect its significant data, to the potential of the efficacy of alternative treatment options related to hemp-derived cannabidiol (CBD) therapies, psilocybin and other psychedelic plant-based treatment options.

ON BEHALF OF THE BOARD OF DIRECTORS:

Steven McAuley
Chief Executive Officer

CONTACTS:

Investors: Steven McAuley

Chairman & CEO

[email protected]

604-789-2146

Investors: Dustin Klein

SVP, Business Development

[email protected]

720-352-1398

For French inquiries: Remy Scalabrini, Maricom Inc., E: [email protected], T: (888) 585-MARI

DISCLAIMER FOR FORWARD-LOOKING STATEMENTS

This news release contains certain “forward-looking statements” or “forward-looking information” (collectively “forward looking statements”) within the meaning of applicable Canadian securities laws. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release.Forward-looking statements can frequently be identified by words such as “plans”, “continues”, “expects”, “projects”, “intends”, “believes”, “anticipates”, “estimates”, “may”, “will”, “potential”, “proposed” and other similar words, or information that certain events or conditions “may” or “will” occur. Forward-looking statements in this news release include statements regarding: the Company’s expected timing of filing of its Annual Filings, the Company’s intention to create psilocybin and psychedelics divisions, that market research on advancements in psilocybin and psychedelics in North America and globally will create greater shareholder value, the Company’s intention to open a hemp-based CBD extraction facility, the expected benefits to the Company and its shareholders as a result of the proposed acquisitions and partnerships; the effectiveness of the extraction technology; the expected benefits for Empowers patient base and customers; the benefits of CBD based products; the effect of the approval of the Farm Bill; the growth of the Company’s patient list and that the Company will be positioned to be a market-leading service provider for complex patient requirements in 2019 and beyond; the ability of the Company to complete or execute phases One, Two, Three or Four of COVID-19 test programs, and Psychedelic substances remain illegal in most countries, so please reference your local laws in relation to medical or recreational use. Such statements are only projections, are based on assumptions known to management at this time, and are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including; that the Company may not open a hemp-based CBD extraction facility; that legislative changes may have an adverse effect on the Company’s business and product development; that the Company may not be able to obtain adequate financing to pursue its business plan; general business, economic, competitive, political and social uncertainties; failure to obtain any necessary approvals in connection with the proposed acquisitions and partnerships; and other factors beyond the Company’s control. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are cautioned not to place undue reliance on the forward-looking statements in this release, which are qualified in their entirety by these cautionary statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements in this release, whether as a result of new information, future events or otherwise, except as expressly required by applicable laws.

SOURCE: Empower Clinics Inc.

VIDEO – Empower Clinics $CBDT.ca Is The Quiet Giant Killer With 165,000 Patient Database For #CBD, #Wellness, #COVID19 Testing and #Psychedelics $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca

Posted by AGORACOM-JC at 9:05 PM on Sunday, June 28th, 2020

With 165,000 patients, Empower Clinics (CBDT:CSE) (EPWCF:OTCQB) has a database that almost every medical cannabis and CBD company would kill for.  Patient visits increased 800% in February. 590% in March and 480% for Q1.   These are actual patients that are suffering from:

  • Anxiety
  • Depression
  • Chronic Pain
  • PTSD

… and need CBD medication to cope with life, as well as, life’s biggest curve ball in modern history …. COVID-19.  To this end, Empower Clinics has not only been administering COVID-19 tests in their clinics way ahead of anyone, they are simultaneously onboarding more employees than anytime in history.

But it gets even better.  Empower is now moving into the lucrative Phase 3 of their COVD-19 testing roll-out …. mass testing of employees for business.  Companies are already signing up en masse on the Empower website and paying in advance for Empower teams to show up at their place of business to test employees.  We’re not even going to talk about Phase 4, which you’re going to have to hear for yourself in this interview.   

PSYCHEDELICS – DOSED MOVIE

With this kind of platform (6 clinics + tele-medinice platform) and execution, is it any wonder to you that Empower Clinics has launched “Dosed Wellness” to incorporate Psychedelics into its platform?  Don’t take our word for it, believe Tyler Chandler, Director of DOSED Movie, an award-winning documentary about treatment using psychedelic medicine who stated:

“Empower Clinics has the strategic vision, existing client base and clinic network to continue to lead the plant-based medicine industry”

This platform and deployment demonstrates a military precision process that few small cap CEO’s could handle.  But Steven McAuley is no ordinary small cap CEO. He is Six Sigma certified under the quality initiative of legendary GE (General Electric) Chairman Jack Welch. We’ve never seen a Six Sigma certified CEO in the Canadian small cap markets. Never …. which explains how McAuley has been able to guide Empower Clinics through the most disruptive retail environment in recent history and turn it into significant growth.

Forget NetFlix Tonight.  Watch this.

Watch this interview or listen by Podcast on Apple, Google, Spotify or your favourite podcaster.

Empower $CBDT.ca to Open Wellness Clinic in Vancouver and Provides Updates on Its #Psychedlics Division Dosed Wellness $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca

Posted by AGORACOM-JC at 7:04 AM on Thursday, June 25th, 2020
  • Company has commenced facility searches in the greater Vancouver market to open a wellness clinic supporting the launch of Dosed Wellness and to serve as a local headquarters for Company staff
  • “We continue to see record numbers of patients in our clinics, patients seeking support for anxiety, depression, and PTSD.” said Steven McAuley, Chairman & CEO of Empower. “Our continued advancements in the psychedelics sector has the potential to improve the mental health outcome of millions of people.”

VANCOUVER BC / June 25, 2020 / EMPOWER CLINICS INC. (CSE:CBDT)(OTCQB:EPWCF)(Frankfurt:8EC) (“Empower” or the “Company“), a vertically integrated life sciences company, is pleased to announce that the Company has commenced facility searches in the greater Vancouver market to open a wellness clinic supporting the launch of Dosed Wellness and to serve as a local headquarters for Company staff.

The Company also confirms significant progress has been made with negotiations on the definitive agreement related to the previously announced non-binding term sheet with Golden Teacher Films Inc. (“Golden”), to acquire a 10% interest in certain royalty rights, intellectual property rights and interest in Dosed Movie (“DOSED”), an award-wining documentary film about treating anxiety, depression and addiction with psychedelic medicine.

“We continue to see record numbers of patients in our clinics, patients seeking support for anxiety, depression, and PTSD.” said Steven McAuley, Chairman & CEO of Empower. “Our continued advancements in the psychedelics sector has the potential to improve the mental health outcome of millions of people.”

“Our team is well connected in the psychedelic space and our expertise on the media side will help elevate the Empower brand. We’re also excited that Empower Clinics is acquiring an interest in DOSED, as their promotion of the film will help educate millions of people about the opportunities inherent in psychedelic medicine.” said Nicholas Meyers, Producer of DOSED.

“Widespread legalization of psilocybin and psychedelics is inevitable, as clinical research is showing these compounds are uniquely useful for treating mental illness and addiction.” said Tyler Chandler, Director of DOSED. “Since billions of people worldwide suffer from these conditions, we need to establish infrastructure and patient-care competencies to serve this population as soon as the law allows. We’re thrilled to align with Empower Clinics, which has the strategic vision, existing client base and clinic network to continue to lead the plant-based medicine industry.”

  • Dosed Wellness Dosed Wellness Ltd. and a new dedicated website www.dosedwellness.com leverages the operating assets of Empower. Dosed Wellness is uniquely positioned as an early mover in the psychedelics space with a network of physicians and clinics, advanced research opportunities, tele-medicine capabilities, and a growing base of over 165,000 patients.
  • Psychedelics Market The mental health crisis could cost the world $16 trillion by 2030 and according to Future Market Insights; the global behavioral health (non-pharmacological) market is expected to be valued at US$156 billion by 2028. According to the World Health Organization depression is already the leading cause of disability worldwide (more than 322 million people suffer from depression) and is a major contributor to the overall global burden of disease.
  • Tele-Medicine The Company provides tele-medicine services to patients in Arizona, Oregon and Washington State, and the platform will be made available to Canadian patients, in conjunction with the opening of the Vancouver wellness clinic.

Learn more about our new psychedelic’s division at www.dosedwellness.com

ABOUT EMPOWER

Empower is a vertically integrated health & wellness company with a network of corporate and franchised health & wellness clinics in the U.S. The Company is focused on helping patients improve and protect their health, through innovative physician recommended treatment options. The Company has launched Dosed Wellness Ltd. to connect its significant data, to the potential of the efficacy of alternative treatment options related to hemp-derived cannabidiol (CBD) therapies, psilocybin and other psychedelic plant-based treatment options.

About Dosed Movie

After many years of prescription medications failing her, a suicidal woman turns to underground healers to try and overcome her depression, anxiety, and opioid addiction with illegal psychedelic medicine such as magic mushrooms and iboga. Adrianne’s first dose of psilocybin mushrooms catapulted her into an unexpected world of healing where plant medicines are redefining our understanding of mental health and addiction. DOSED is directed and produced by Tyler Chandler and Nicholas Meyers is producer and director of photography.

Visit www.dosedmovie.com to rent or own DOSED.

ON BEHALF OF THE BOARD OF DIRECTORS:

Steven McAuley
Chief Executive Officer

CONTACTS:

Investors: Steven McAuley
Chairman & CEO
[email protected]
604-789-2146

Investors: Dustin Klein
SVP, Business Development
[email protected]
720-352-1398

For French inquiries: Remy Scalabrini, Maricom Inc., E: [email protected], T: (888) 585-MARI

DISCLAIMER FOR FORWARD-LOOKING STATEMENTS

This news release contains certain “forward-looking statements” or “forward-looking information” (collectively “forward looking statements”) within the meaning of applicable Canadian securities laws. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release.Forward-looking statements can frequently be identified by words such as “plans”, “continues”, “expects”, “projects”, “intends”, “believes”, “anticipates”, “estimates”, “may”, “will”, “potential”, “proposed” and other similar words, or information that certain events or conditions “may” or “will” occur. Forward-looking statements in this news release include statements regarding: the Company’s expected timing of filing of its Annual Filings, the Company’s intention to create psilocybin and psychedelics divisions, that market research on advancements in psilocybin and psychedelics in North America and globally will create greater shareholder value, the Company’s intention to open a hemp-based CBD extraction facility, the expected benefits to the Company and its shareholders as a result of the proposed acquisitions and partnerships; the effectiveness of the extraction technology; the expected benefits for Empowers patient base and customers; the benefits of CBD based products; the effect of the approval of the Farm Bill; the growth of the Company’s patient list and that the Company will be positioned to be a market-leading service provider for complex patient requirements in 2019 and beyond; the ability of the Company to complete or execute phases One, Two, Three or Four of COVID-19 test programs, and Psychedelic substances remain illegal in most countries, so please reference your local laws in relation to medical or recreational use. Such statements are only projections, are based on assumptions known to management at this time, and are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including; that the Company may not open a hemp-based CBD extraction facility; that legislative changes may have an adverse effect on the Company’s business and product development; that the Company may not be able to obtain adequate financing to pursue its business plan; general business, economic, competitive, political and social uncertainties; failure to obtain any necessary approvals in connection with the proposed acquisitions and partnerships; and other factors beyond the Company’s control. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are cautioned not to place undue reliance on the forward-looking statements in this release, which are qualified in their entirety by these cautionary statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements in this release, whether as a result of new information, future events or otherwise, except as expressly required by applicable laws.

Steven McAuley, Empower Clinics $CBDT.ca CEO to Speak at Peak Asset Management’s Psychedelic Investment Webinar and Provides Corporate Update $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca

Posted by AGORACOM-JC at 6:46 AM on Tuesday, June 16th, 2020

Empower CEO, Steven McAuley, will speak at the Peak Asset Management’s Webinar on Thursday June 18th at 7:30PST

Management Cease Trade Order has been approved by BC Securities Commission effective June 16, 2020

– “Having the opportunity to participate in the Peak Asset Management’s Psychedelics Webinar in front of a diverse international audience, allows me to advocate for the impact psychedelic treatments may have for global mental health issues.” said Steven McAuley, Chairman & CEO of Empower. “Being part of the conversation on behalf of our new psychedelics division Dosed Wellness, brings important exposure to the overall narrative.”

VANCOUVER BC /June 16, 2020 / EMPOWER CLINICS INC. (CSE:CBDT)(OTCQB:EPWCF)(Frankfurt:8EC) (“Empower” or the “Company“), a vertically integrated life sciences company, is pleased to announce that Empower CEO Steven McAuley will be speaking at the Peak Asset Management’s Psychedelic Investment Webinar this Thursday, June 18th at 7:30PST. The Webinar is titled: “Psychedelic Stocks On The Charge in North America Creates Opportunities for Global Investors” and is being hosted by Peter Hunt, Co-founder and Chair of Mind Medicine Australia.

The Webinar will include talks and Q&A from the following Companies:

  • Mind Medicine Australia – working with the Therapeutic Goods Administration to bring these medicines to everyday Australians
  • Eleusian Biosciences Corp – leveraging Psilocybin to treat depression & concussion
  • Empower Clinics – operates six health & wellness clinics in the USA treating patients in real-time ,in person and through tele-medicine

More information and registration for the webinar can be found at: Psychedelic Stocks on the Charge (CTR Click)

“Having the opportunity to participate in the Peak Asset Management’s Psychedelics Webinar in front of a diverse international audience, allows me to advocate for the impact psychedelic treatments may have for global mental health issues.” said Steven McAuley, Chairman & CEO of Empower. “Being part of the conversation on behalf of our new psychedelics division Dosed Wellness, brings important exposure to the overall narrative.”

The Company has amended the application for a management cease trade order (“MCTO“) from filing with the Ontario Securities Commission to an updated filing with the British Columbia Securities Commission, which would restrict all trading in securities of the Company, whether direct or indirect, by the Chief Executive Officer and Chief Financial Officer of the Company. The issuance of an MCTO does not generally affect the ability of persons who are not directors, officers or other insiders of the Company to trade in securities of the Company.

The Company confirms that the BC Securities Commission has approved the application for MCTO effective June 16, 2020

As required under section 9 b) of the National Policy 12-203 – Cease Trade Orders the Company indicates it is unable to meet the prescribed filing deadline due to additional audit requirements by its auditor MNP, LLP and due to increased operational limitations related to the coronavirus pandemic.

The Company intends to comply with the provisions of the alternative information guidelines as set out in the National Policy 12-203 – Cease Trade Orders for Continuous Disclosure Defaults for as long as it remains in default, including the issuance of bi-weekly default status reports, each of which will be issued in the form of a news release.

ABOUT EMPOWER

Empower is a vertically integrated health & wellness company with a network of corporate and franchised health & wellness clinics in the U.S. The Company is focused on helping patients improve and protect their health, through innovative physician recommended treatment options. The Company has launched Dosed Wellness Ltd. to connect its significant data, to the potential of the efficacy of alternative treatment options related to hemp-derived cannabidiol (CBD) therapies, psilocybin and other psychedelic plant-based treatment options.

ON BEHALF OF THE BOARD OF DIRECTORS:

Steven McAuley
Chief Executive Officer

CONTACTS:

Investors: Steven McAuley
Chairman & CEO
[email protected]
604-789-2146

Investors: Dustin Klein
SVP, Business Development
[email protected]

720-352-1398

For French inquiries:

Remy Scalabrini, Maricom Inc.,
E: [email protected],
T: (888) 585-MARI

DISCLAIMER FOR FORWARD-LOOKING STATEMENTS

This news release contains certain “forward-looking statements” or “forward-looking information” (collectively “forward looking statements”) within the meaning of applicable Canadian securities laws. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release.Forward-looking statements can frequently be identified by words such as “plans”, “continues”, “expects”, “projects”, “intends”, “believes”, “anticipates”, “estimates”, “may”, “will”, “potential”, “proposed” and other similar words, or information that certain events or conditions “may” or “will” occur. Forward-looking statements in this news release include statements regarding: the Company’s expected timing of filing of its Annual Filings, the Company’s intention to create psilocybin and psychedelics divisions, that market research on advancements in psilocybin and psychedelics in North America and globally will create greater shareholder value, the Company’s intention to open a hemp-based CBD extraction facility, the expected benefits to the Company and its shareholders as a result of the proposed acquisitions and partnerships; the effectiveness of the extraction technology; the expected benefits for Empowers patient base and customers; the benefits of CBD based products; the effect of the approval of the Farm Bill; the growth of the Company’s patient list and that the Company will be positioned to be a market-leading service provider for complex patient requirements in 2019 and beyond; the ability of the Company to complete or execute phases One, Two, Three or Four of COVID-19 test programs, and Psychedelic substances remain illegal in most countries, so please reference your local laws in relation to medical or recreational use. Such statements are only projections, are based on assumptions known to management at this time, and are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including; that the Company may not open a hemp-based CBD extraction facility; that legislative changes may have an adverse effect on the Company’s business and product development; that the Company may not be able to obtain adequate financing to pursue its business plan; general business, economic, competitive, political and social uncertainties; failure to obtain any necessary approvals in connection with the proposed acquisitions and partnerships; and other factors beyond the Company’s control. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are cautioned not to place undue reliance on the forward-looking statements in this release, which are qualified in their entirety by these cautionary statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements in this release, whether as a result of new information, future events or otherwise, except as expressly required by applicable laws.

SOURCE: Empower Clinics Inc.